Who makes C. difficile vaccine formulation 2.?

C. difficile vaccine formulation 2. is developed by Pfizer Inc..

What development phase is C. difficile vaccine formulation 2. in?

C. difficile vaccine formulation 2. is in Phase 1.

What is the generic name of C. difficile vaccine formulation 2.?

c-difficile-vaccine-formulation-2 is the generic (nonproprietary) name of C. difficile vaccine formulation 2..

Last reviewed 2026-04-20 · How we verify

C. difficile vaccine formulation 2. (c-difficile-vaccine-formulation-2)

Pfizer Inc. · Phase 1 active Vaccine Quality 0/100

At a glance

Generic name	c-difficile-vaccine-formulation-2
Sponsor	Pfizer Inc.
Modality	Vaccine
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

C. difficile vaccine formulation 2. CI brief — competitive landscape report
C. difficile vaccine formulation 2. updates RSS · CI watch RSS
Pfizer Inc. portfolio CI